Platform & Pipeline


CRLX301, the second candidate from our platform, is an NDC with a docetaxel payload. Docetaxel is a commercially successful oncology drug that suffers from a poor safety profile that limits its clinical utility. We believe that CRLX301 will be differentiated from docetaxel because it is designed to concentrate more docetaxel in tumor cells and spare healthy tissue.